{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T11:01:00Z","timestamp":1785150060051,"version":"3.55.0"},"reference-count":446,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019779","name":"Qatar National Library","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019779","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["pharmrev.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reviews"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.pharmr.2026.100136","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T17:03:10Z","timestamp":1775840590000},"page":"100136","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacogenomics of antibacterial and antiviral therapies: Clinical actionability, evidence gaps, and future directions"],"prefix":"10.1016","volume":"78","author":[{"given":"Maria K.","family":"Smatti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zainab","family":"Jan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7621-0130","authenticated-orcid":false,"given":"Hadi M.","family":"Yassine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.pharmr.2026.100136_bib1","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/d41573-022-00120-3","article-title":"Human genetics evidence supports two-thirds of the 2021 FDA-approved drugs","volume":"21","author":"Ochoa","year":"2022","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100136_bib2","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S1471-4914(01)01986-4","article-title":"Clinical application of pharmacogenetics","volume":"7","author":"Spear","year":"2001","journal-title":"Trends Mol Med"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100136_bib3","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/biostatistics\/kxx069","article-title":"Estimation of clinical trial success rates and related parameters","volume":"20","author":"Wong","year":"2019","journal-title":"Biostatistics"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100136_bib4","article-title":"From pharmacogenetics to pharmaco-omics: milestones and future directions","volume":"3","author":"Auwerx","year":"2022","journal-title":"HGG Adv"},{"key":"10.1016\/j.pharmr.2026.100136_bib5","series-title":"Pharmacogenomics in Clinical Practice","first-page":"105","article-title":"Pharmacogenetic algorithms","author":"Esquivel","year":"2023"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100136_bib6","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1080\/03602532.2024.2385928","article-title":"Insights into pharmacogenetics, drug-gene interactions, and drug-drug-gene interactions","volume":"57","author":"Russell","year":"2024","journal-title":"Drug Metab Rev"},{"issue":"17","key":"10.1016\/j.pharmr.2026.100136_bib7","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1001\/jama.1952.72930340027010c","article-title":"Toxicity of primaquine in Negroes","volume":"149","author":"Hockwald","year":"1952","journal-title":"J Am Med Assoc"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100136_bib8","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/0163-7258(89)90130-7","article-title":"Pharmacogenetic perspectives gained from twin and family studies","volume":"41","author":"Vesell","year":"1989","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.pharmr.2026.100136_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.837164","article-title":"TPMT and NUDT15 testing for thiopurine therapy: A major tertiary hospital experience and lessons learned","volume":"13","author":"Goh","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.pharmr.2026.100136_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.867490","article-title":"Implementation of HLA-B\u221715:02 genotyping as standard-of-care for reducing carbamazepine\/oxcarbazepine induced cutaneous adverse drug reactions in Thailand","volume":"13","author":"Tiwattanon","year":"2022","journal-title":"Front Pharmacol"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100136_bib11","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1002\/cpt.2526","article-title":"Clinical pharmacogenetics implementation consortium guideline for CYP2C19 genotype and clopidogrel therapy: 2022 update","volume":"112","author":"Lee","year":"2022","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100136_bib12","doi-asserted-by":"crossref","DOI":"10.1002\/wsbm.1417","article-title":"PharmGKB: A worldwide resource for pharmacogenomic information","volume":"10","author":"Barbarino","year":"2018","journal-title":"Wiley Interdiscip Rev Syst Biol Med"},{"issue":"10398","key":"10.1016\/j.pharmr.2026.100136_bib13","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0140-6736(23)00860-7","article-title":"The unfinished agenda of communicable diseases among children and adolescents before the COVID-19 pandemic, 1990\u20132019: a systematic analysis of the Global Burden of Disease Study 2019","volume":"402","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.pharmr.2026.100136_bib15","author":"Walsh"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100136_bib16","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jinf.2023.01.020","article-title":"Changes in the prevalence of infectious diseases before and after the COVID-19 pandemic in Pakistan","volume":"86","author":"Rana","year":"2023","journal-title":"J Infect"},{"key":"10.1016\/j.pharmr.2026.100136_bib17","doi-asserted-by":"crossref","DOI":"10.1177\/20420986241251593","article-title":"The crucial role of pharmacovigilance in managing infectious diseases in lower and middle-income countries","volume":"15","author":"Khan","year":"2024","journal-title":"Ther Adv Drug Saf"},{"key":"10.1016\/j.pharmr.2026.100136_bib18","author":"Johnson"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100136_bib19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41397-024-00326-1","article-title":"A review of real-world evidence on preemptive pharmacogenomic testing for preventing adverse drug reactions: a reality for future health care","volume":"24","author":"Chenchula","year":"2024","journal-title":"Pharmacogenomics J"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100136_bib20","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/pds.3967","article-title":"Fifty years of pharmacovigilance\u2014medicines safety and public health","volume":"25","author":"Laporte","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100136_bib21","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/14737167.2019.1608825","article-title":"Cost implications of adverse drug event-related emergency department visits\u2014a multicenter study in South Korea","volume":"20","author":"Lee","year":"2020","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.pharmr.2026.100136_bib22","series-title":"New Insights into the Future of Pharmacoepidemiology and Drug Safety","article-title":"Prevalence and significance of antibiotic-associated adverse reactions","author":"T\u00e2nia Magalh\u00e3es","year":"2021"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100136_bib23","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/cpt.677","article-title":"Adverse drug reactions in children: the double-edged sword of therapeutics","volume":"101","author":"Elzagallaai","year":"2017","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100136_bib24","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/jpids\/piac121","article-title":"Adverse drug reactions to anti-infectives in hospitalized children: a multicenter study in Brazil","volume":"12","author":"Feitosa Ramos","year":"2023","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100136_bib25","doi-asserted-by":"crossref","first-page":"481","DOI":"10.7861\/clinmedicine.16-5-481","article-title":"Adverse drug reactions","volume":"16","author":"Coleman","year":"2016","journal-title":"Clin Med (Lond)"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100136_bib26","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s41999-021-00481-9","article-title":"Adverse drug reactions in older adults: a narrative review of the literature","volume":"12","author":"Zazzara","year":"2021","journal-title":"Eur Geriatr Med"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100136_bib27","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1093\/jac\/dkx183","article-title":"Quantification of the risk of liver injury associated with flucloxacillin: a UK population-based cohort study","volume":"72","author":"Wing","year":"2017","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100136_bib28","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jsps.2013.02.003","article-title":"Factors affecting the development of adverse drug reactions (Review article)","volume":"22","author":"Alomar","year":"2014","journal-title":"Saudi Pharm J"},{"key":"10.1016\/j.pharmr.2026.100136_bib29","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/bs.apha.2018.03.002","article-title":"Pharmacogenetics of adverse drug reactions","volume":"83","author":"Osanlou","year":"2018","journal-title":"Adv Pharmacol"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100136_bib30","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s40273-016-0397-9","article-title":"A systematic review of economic evaluations of pharmacogenetic testing for prevention of adverse drug reactions","volume":"34","author":"Plumpton","year":"2016","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100136_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41431-019-0499-x","article-title":"Sketching the prevalence of pharmacogenomic biomarkers among populations for clinical pharmacogenomics","volume":"28","author":"Patrinos","year":"2020","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.pharmr.2026.100136_bib32","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/978-1-60761-663-4_7","article-title":"DMET microarray technology for pharmacogenomics-based personalized medicine","volume":"632","author":"Burmester","year":"2010","journal-title":"Methods Mol Biol"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100136_bib33","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.2217\/pgs.14.102","article-title":"Personalized pharmacogenomics profiling using whole-genome sequencing","volume":"15","author":"Mizzi","year":"2014","journal-title":"Pharmacogenomics"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100136_bib34","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3390\/genes11050561","article-title":"Exome-wide analysis of the DiscovEHR cohort reveals novel candidate pharmacogenomic variants for clinical pharmacogenomics","volume":"11","author":"Pandi","year":"2020","journal-title":"Genes"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100136_bib35","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/gim.2016.33","article-title":"Rare genetic variants in cellular transporters, metabolic enzymes, and nuclear receptors can be important determinants of interindividual differences in drug response","volume":"19","author":"Kozyra","year":"2017","journal-title":"Genet Med"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100136_bib36","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.tips.2022.07.002","article-title":"Challenges and opportunities associated with rare-variant pharmacogenomics","volume":"43","author":"Zhou","year":"2022","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.pharmr.2026.100136_bib37","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1146\/annurev-pharmtox-051921-091209","article-title":"Pharmacogenomics beyond single common genetic variants: the way forward","volume":"64","author":"Lauschke","year":"2024","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"5197","key":"10.1016\/j.pharmr.2026.100136_bib38","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1136\/bmj.2.5197.485","article-title":"Genetic control of isoniazid metabolism in man","volume":"2","author":"Evans","year":"1960","journal-title":"Br Med J"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100136_bib39","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1021\/tx700079z","article-title":"Cytochrome P450 and chemical toxicology","volume":"21","author":"Guengerich","year":"2008","journal-title":"Chem Res Toxicol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100136_bib40","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/03602530902843483","article-title":"Polymorphism of human cytochrome P450 enzymes and its clinical impact","volume":"41","author":"Zhou","year":"2009","journal-title":"Drug Metab Rev"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100136_bib41","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1093\/jac\/dku315","article-title":"CYP2B6 c.983T>C polymorphism is associated with nevirapine hypersensitivity in Malawian and Ugandan HIV populations","volume":"69","author":"Carr","year":"2014","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100136_bib42","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1007\/s00228-013-1549-x","article-title":"Association between CYP2B6 polymorphisms and nevirapine-induced SJS\/TEN: a pharmacogenetics study","volume":"69","author":"Ciccacci","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100136_bib43","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/jac\/dkw032","article-title":"Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications","volume":"71","author":"Marzolini","year":"2016","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100136_bib44","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/cpt.156","article-title":"Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily efavirenz (400 mg vs. 600 mg) in Treatment-Na\u00efve HIV-Infected Patients: results of the ENCORE1 Study","volume":"98","author":"Dickinson","year":"2015","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100136_bib45","doi-asserted-by":"crossref","first-page":"103","DOI":"10.5507\/bp.2010.017","article-title":"Phase II drug metabolizing enzymes","volume":"154","author":"Jancova","year":"2010","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100136_bib46","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/cpt.269","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for UGT1A1 and atazanavir prescribing","volume":"99","author":"Gammal","year":"2016","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100136_bib47","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1097\/00008571-200012000-00007","article-title":"Prospective evaluation of detoxification pathways as markers of cutaneous adverse reactions to sulphonamides in AIDS","volume":"10","author":"Wolkenstein","year":"2000","journal-title":"Pharmacogenetics"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100136_bib48","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jcma.2014.01.010","article-title":"Recent progress in genetic variation and risk of antituberculosis drug-induced liver injury","volume":"77","author":"Huang","year":"2014","journal-title":"J Chin Med Assoc"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100136_bib49","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.gpb.2016.03.008","article-title":"Pharmacogenomics of drug metabolizing enzymes and transporters: relevance to precision medicine","volume":"14","author":"Ahmed","year":"2016","journal-title":"Genomics Proteomics Bioinformatics"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100136_bib50","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3028","article-title":"Membrane transporters in drug development","volume":"9","author":"Giacomini","year":"2010","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100136_bib51","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41573-023-00877-1","article-title":"Membrane transporters in drug development and as determinants of precision medicine","volume":"23","author":"Galetin","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.pharmr.2026.100136_bib52","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/978-1-0716-1554-6_8","article-title":"The structure and mechanism of drug transporters","volume":"2342","author":"Roberts","year":"2021","journal-title":"Methods Mol Biol"},{"issue":"2\u20133","key":"10.1016\/j.pharmr.2026.100136_bib53","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.mam.2012.10.009","article-title":"The SLCO (former SLC21) superfamily of transporters","volume":"34","author":"Hagenbuch","year":"2013","journal-title":"Mol Aspects Med"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100136_bib54","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1002\/jps.23581","article-title":"Reduced renal clearance of cefotaxime in Asians with a low-frequency polymorphism of OAT3 (SLC22A8)","volume":"102","author":"Yee","year":"2013","journal-title":"J Pharm Sci"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100136_bib55","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1476-5381.2009.00430.x","article-title":"Impact of OATP transporters on pharmacokinetics","volume":"158","author":"Kalliokoski","year":"2009","journal-title":"Br J Pharmacol"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100136_bib56","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/clpt.2012.106","article-title":"OATP1B1 polymorphism as a determinant of erythromycin disposition","volume":"92","author":"Lancaster","year":"2012","journal-title":"Clin Pharmacol Ther"},{"issue":"17","key":"10.1016\/j.pharmr.2026.100136_bib57","doi-asserted-by":"crossref","first-page":"9371","DOI":"10.3390\/ijms25179371","article-title":"Receptor pharmacogenomics: deciphering genetic influence on drug response","volume":"25","author":"Anghel","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100136_bib58","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.3390\/ijms21072583","article-title":"Interferon response in hepatitis C virus-infected hepatocytes: issues to consider in the era of direct-acting antivirals","volume":"21","author":"Sung","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100136_bib59","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S2055-6640(20)31150-X","article-title":"HIV-1 resistance to dolutegravir: update and new insights","volume":"1","author":"Wainberg","year":"2015","journal-title":"J Virus Erad"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100136_bib60","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0122844","article-title":"Direct binding of ledipasvir to HCV NS5A: mechanism of resistance to an HCV antiviral agent","volume":"10","author":"Kwon","year":"2015","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100136_bib61","doi-asserted-by":"crossref","first-page":"MGM2","DOI":"10.1128\/microbiolspec.MGM2-0014-2013","article-title":"Resistance to isoniazid and ethionamide in Mycobacterium tuberculosis: genes, mutations, and causalities","volume":"2","author":"Vilch\u00e8ze","year":"2014","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.pharmr.2026.100136_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.virol.2024.110375","article-title":"Targeting CCR5: a central approach to HIV treatment and cure strategies","volume":"603","author":"Yukselten","year":"2025","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100136_bib63","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12864-015-1233-x","article-title":"Sequence and analysis of a whole genome from Kuwaiti population subgroup of Persian ancestry","volume":"16","author":"Thareja","year":"2015","journal-title":"BMC Genomics"},{"key":"10.1016\/j.pharmr.2026.100136_bib64","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1067463","article-title":"HLA variants have different preferences to present proteins with specific molecular functions which are complemented in frequent haplotypes","volume":"13","author":"Karnaukhov","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.pharmr.2026.100136_bib65","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/3186328","article-title":"HLA association with drug-induced adverse reactions","volume":"2017","author":"Fan","year":"2017","journal-title":"J Immunol Res"},{"key":"10.1016\/j.pharmr.2026.100136_bib66","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1146\/annurev-pharmtox-052120-014115","article-title":"HLA allele-restricted immune-mediated adverse drug reactions: framework for genetic prediction","volume":"62","author":"Jaruthamsophon","year":"2022","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100136_bib67","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/j.jaip.2022.04.027","article-title":"Practical implementation of genetics: new concepts in Immunogenomics to predict, prevent, and diagnose drug hypersensitivity","volume":"10","author":"Deshpande","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100136_bib68","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1093\/toxsci\/kfaa124","article-title":"Identification of flucloxacillin-haptenated HLA-B\u221757:01 ligands: evidence of antigen processing and presentation","volume":"177","author":"Waddington","year":"2020","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.pharmr.2026.100136_bib69","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.658593","article-title":"Characterization of T-cell responses to SMX and SMX-NO in co-trimoxazole hypersensitivity patients expressing HLA-B\u221713:01","volume":"12","author":"Pratoomwun","year":"2021","journal-title":"Front Immunol"},{"issue":"7404","key":"10.1016\/j.pharmr.2026.100136_bib70","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/nature11147","article-title":"Immune self-reactivity triggered by drug-modified HLA-peptide repertoire","volume":"486","author":"Illing","year":"2012","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100136_bib71","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1002\/cpt.2735","article-title":"Expanded clinical pharmacogenetics implementation consortium guideline for medication use in the context of G6PD genotype","volume":"113","author":"Gammal","year":"2023","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100136_bib72","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/FPC.0b013e32836498f4","article-title":"PharmGKB summary: methylene blue pathway","volume":"23","author":"McDonagh","year":"2013","journal-title":"Pharmacogenet Genomics"},{"issue":"9606","key":"10.1016\/j.pharmr.2026.100136_bib73","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0140-6736(08)60073-2","article-title":"Glucose-6-phosphate dehydrogenase deficiency","volume":"371","author":"Cappellini","year":"2008","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100136_bib74","doi-asserted-by":"crossref","first-page":"615","DOI":"10.2471\/BLT.23.291224","article-title":"New WHO classification of genetic variants causing G6PD deficiency","volume":"102","author":"Luzzatto","year":"2024","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.pharmr.2026.100136_bib75","series-title":"Pharmacogenomics","first-page":"247","article-title":"Chapter 10\u2014Pharmacogenomics in viral diseases","author":"Khaja","year":"2023"},{"issue":"4599","key":"10.1016\/j.pharmr.2026.100136_bib76","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1126\/science.6189183","article-title":"Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS)","volume":"220","author":"Barr\u00e9-Sinoussi","year":"1983","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100136_bib77","doi-asserted-by":"crossref","first-page":"487","DOI":"10.7326\/0003-4819-117-6-487","article-title":"Zidovudine: five years later","volume":"117","author":"McLeod","year":"1992","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100136_bib78","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.tips.2021.10.004","article-title":"Update and latest advances in antiretroviral therapy","volume":"43","author":"Men\u00e9ndez-Arias","year":"2022","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.pharmr.2026.100136_bib79","article-title":"Highly Active Antiretroviral Therapy (HAART)","author":"Julie","year":"2024","journal-title":"StatPearls"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100136_bib81","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/00126334-200312010-00008","article-title":"Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort","volume":"34","author":"O'Brien","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100136_bib82","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0097482","article-title":"Efficacy of initial antiretroviral therapy for HIV-1 infection in adults: a systematic review and meta-analysis of 114 studies with up to 144 weeks' follow-up","volume":"9","author":"Lee","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100136_bib83","first-page":"745","article-title":"Long-Term Virological Suppression Working Group for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. Long-term virological suppression on first-line efavirenz + tenofovir + emtricitabine\/lamivudine for HIV-1","volume":"33","year":"2019","journal-title":"AIDS"},{"key":"10.1016\/j.pharmr.2026.100136_bib84","unstructured":"Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Office of AIDS Research (OAR), National Institutes of Health. Accessed June 11, 2024. https:\/\/clinicalinfo.hiv.gov\/en\/about-clinicalinfo"},{"issue":"9312","key":"10.1016\/j.pharmr.2026.100136_bib85","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/S0140-6736(02)08158-8","article-title":"Genetic variations in HLA-B region and hypersensitivity reactions to abacavir","volume":"359","author":"Hetherington","year":"2002","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100136_bib86","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1517\/phgs.5.2.203.27481","article-title":"Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations","volume":"5","author":"Hughes","year":"2004","journal-title":"Pharmacogenomics"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100136_bib87","doi-asserted-by":"crossref","first-page":"4180","DOI":"10.1073\/pnas.0307067101","article-title":"Predisposition to abacavir hypersensitivity conferred by HLA-b\u22175701 and a haplotypic Hsp70-Hom variant","volume":"101","author":"Martin","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100136_bib88","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1056\/NEJMoa0706135","article-title":"HLA-b\u22175701 screening for hypersensitivity to abacavir","volume":"358","author":"Mallal","year":"2008","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100136_bib89","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1086\/529382","article-title":"High sensitivity of human leukocyte antigen-b\u22175701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients","volume":"46","author":"Saag","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100136_bib90","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.humimm.2011.12.002","article-title":"Human leukocyte antigen (HLA) and pharmacogenetics: screening for HLA-B\u221757:01 among human immunodeficiency virus-positive patients from southern Alberta","volume":"73","author":"Berka","year":"2012","journal-title":"Hum Immunol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100136_bib91","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/FTD.0b013e3181ad74a4","article-title":"Pharmacokinetics of plasma efavirenz and CYP2B6 polymorphism in southern Chinese","volume":"31","author":"To","year":"2009","journal-title":"Ther Drug Monit"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100136_bib92","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2174\/157016212803901338","article-title":"Correlation of CYP2B6-516G > T polymorphism with plasma efavirenz concentration and depression in HIV-infected adults in Northern Thailand","volume":"10","author":"Aurpibul","year":"2012","journal-title":"Curr HIV Res"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100136_bib93","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/tpj.2011.34","article-title":"High plasma efavirenz level and CYP2B6\u22176 are associated with efavirenz-based HAART-induced liver injury in the treatment of na\u00efve HIV patients from Ethiopia: a prospective cohort study","volume":"12","author":"Yimer","year":"2012","journal-title":"Pharmacogenomics J"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100136_bib94","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1111\/jce.13032","article-title":"Efavirenz inhibits the human ether-A-Go-Go related current (hERG) and induces QT interval prolongation in CYP2B6\u22176\u22176 Allele Carriers","volume":"27","author":"Abdelhady","year":"2016","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100136_bib95","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ijantimicag.2015.11.012","article-title":"Efavirenz pharmacogenetics in a cohort of Italian patients","volume":"47","author":"Cusato","year":"2016","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100136_bib96","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/jac\/dkt372","article-title":"Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients","volume":"69","author":"Sarfo","year":"2014","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100136_bib97","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.2217\/pgs.10.94","article-title":"Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients","volume":"11","author":"Elens","year":"2010","journal-title":"Pharmacogenomics"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100136_bib98","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.bjid.2014.01.009","article-title":"Interleukin-10 gene polymorphism (\u22121082G\/A) and allergy to efavirenz in patients infected with human immunodeficiency virus","volume":"18","author":"de Oliveira Rodrigues","year":"2014","journal-title":"Braz J Infect Dis"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100136_bib99","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1089\/aid.2022.0027","article-title":"Association of human leukocyte antigen alleles and hypersensitivity of efavirenz\/nevirapine in HIV-infected Chinese patients","volume":"38","author":"Zhou","year":"2022","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100136_bib100","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.2217\/pgs.13.111","article-title":"Impact of pharmacogenetics on CNS side effects related to efavirenz","volume":"14","author":"S\u00e1nchez Mart\u00edn","year":"2013","journal-title":"Pharmacogenomics"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100136_bib101","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1007\/s00228-017-2295-2","article-title":"Impact of glutathione transferases genes polymorphisms in nevirapine adverse reactions: a possible role for GSTM1 in SJS\/TEN susceptibility","volume":"73","author":"Ciccacci","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100136_bib102","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/FTD.0b013e31824868f3","article-title":"Associations between ABCB1, CYP2A6, CYP2B6, CYP2D6, and CYP3A5 alleles in relation to efavirenz and nevirapine pharmacokinetics in HIV-infected individuals","volume":"34","author":"Heil","year":"2012","journal-title":"Ther Drug Monit"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100136_bib103","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1089\/omi.2015.0104","article-title":"Effects of CYP2B6 and CYP1A2 genetic variation on nevirapine plasma concentration and pharmacodynamics as measured by CD4 cell count in Zimbabwean HIV-infected patients","volume":"19","author":"Mhandire","year":"2015","journal-title":"OMICS"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100136_bib104","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2217\/pgs.09.142","article-title":"Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique","volume":"11","author":"Ciccacci","year":"2010","journal-title":"Pharmacogenomics"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100136_bib105","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1097\/QAD.0b013e32834779df","article-title":"Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent","volume":"25","author":"Yuan","year":"2011","journal-title":"AIDS"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100136_bib106","doi-asserted-by":"crossref","first-page":"114","DOI":"10.4103\/0976-500X.81905","article-title":"HLA involvement in nevirapine-induced dermatological reaction in antiretroviral-treated HIV-1 patients","volume":"2","author":"Umapathy","year":"2011","journal-title":"J Pharmacol Pharmacother"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100136_bib107","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1093\/jac\/dky180","article-title":"A multivariate genetic analysis confirms rs5010528 in the human leucocyte antigen-C locus as a significant contributor to Stevens-Johnson syndrome\/toxic epidermal necrolysis susceptibility in a Mozambique HIV population treated with nevirapine","volume":"73","author":"Ciccacci","year":"2018","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100136_bib108","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/cid\/cir403","article-title":"Genome-wide association study identifies variations in 6p21.3 associated with nevirapine-induced rash","volume":"53","author":"Chantarangsu","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100136_bib109","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1093\/jac\/dkp317","article-title":"Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors","volume":"64","author":"Anderson","year":"2009","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100136_bib110","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1086\/653427","article-title":"Genetic factors influencing severe atazanavir-associated hyperbilirubinemia in a population with low UDP-glucuronosyltransferase 1A1\u221728 allele frequency","volume":"51","author":"Park","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100136_bib111","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/FPC.0000000000000316","article-title":"Race\/ethnicity difference in the pharmacogenetics of bilirubin-related atazanavir discontinuation","volume":"28","author":"Leger","year":"2018","journal-title":"Pharmacogenet Genomics"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100136_bib112","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/infdis\/jis690","article-title":"Impact of UGT1A1 Gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS Clinical Trials Group Study A5202","volume":"207","author":"Ribaudo","year":"2013","journal-title":"J Infect Dis"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100136_bib113","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1089\/aid.2013.0002","article-title":"Clinical and pharmacogenetic factors affecting neonatal bilirubinemia following atazanavir treatment of mothers during pregnancy","volume":"29","author":"Eley","year":"2013","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100136_bib114","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1086\/592304","article-title":"Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C-->T) with reduced concentrations of unboosted atazanavir","volume":"47","author":"Siccardi","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100136_bib115","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/FPC.0000000000000040","article-title":"PharmGKB summary: abacavir pathway","volume":"24","author":"Barbarino","year":"2014","journal-title":"Pharmacogenet Genomics"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100136_bib116","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1001\/jama.2012.7961","article-title":"Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel","volume":"308","author":"Thompson","year":"2012","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100136_bib117","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/clpt.2011.355","article-title":"Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing","volume":"91","author":"Martin","year":"2012","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100136_bib118","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1097\/00002030-199907300-00026","article-title":"Abacavir rechallenge has to be avoided in case of hypersensitivity reaction","volume":"13","author":"Escaut","year":"1999","journal-title":"AIDS"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100136_bib119","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1046\/j.1468-1293.2003.00166.x","article-title":"Epidemiological risk factors for hypersensitivity reactions to abacavir","volume":"4","author":"Easterbrook","year":"2003","journal-title":"HIV Med"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100136_bib120","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0149-2918(02)85132-3","article-title":"Risk factor analysis of hypersensitivity reactions to abacavir","volume":"24","author":"Symonds","year":"2002","journal-title":"Clin Ther"},{"issue":"16","key":"10.1016\/j.pharmr.2026.100136_bib121","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1097\/00002030-200211080-00017","article-title":"Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir","volume":"16","author":"Phillips","year":"2002","journal-title":"AIDS"},{"issue":"9308","key":"10.1016\/j.pharmr.2026.100136_bib122","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0140-6736(02)07873-X","article-title":"Association between presence of HLA-b\u22175701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir","volume":"359","author":"Mallal","year":"2002","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100136_bib123","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/FPC.0b013e3283390666","article-title":"An epidemiologic study to determine the prevalence of the HLA-b\u22175701 allele among HIV-positive patients in Europe","volume":"20","author":"Orkin","year":"2010","journal-title":"Pharmacogenet Genomics"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100136_bib124","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12865-021-00427-7","article-title":"Prevalence of human leukocyte antigen HLA-B\u221757:01 in individuals with HIV in West and Central Africa","volume":"22","author":"Kolou","year":"2021","journal-title":"BMC Immunol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100136_bib125","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1186\/s12879-019-4415-3","article-title":"HLA-B\u221757:01 allele prevalence in treatment-Na\u00efve HIV-infected patients from Colombia","volume":"19","author":"Mart\u00ednez Buitrago","year":"2019","journal-title":"BMC Infect Dis"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100136_bib126","doi-asserted-by":"crossref","first-page":"195","DOI":"10.4103\/npmj.npmj_75_19","article-title":"Absence of human leukocyte antigen-B\u221757:01 amongst patients on antiretroviral therapy in Nigeria: implications for use of abacavir","volume":"26","author":"Agbaji","year":"2019","journal-title":"Niger Postgrad Med J"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100136_bib127","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1468-1293.2009.00762.x","article-title":"Prospective epidemiological study of the prevalence of human leukocyte antigen (HLA)-B\u22175701 in HIV-1-infected UK subjects","volume":"11","author":"Orkin","year":"2010","journal-title":"HIV Med"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100136_bib128","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2217\/17410541.5.3.297","article-title":"HLA-B\u22175701 screening for hypersensitivity to abacavir","volume":"5","author":"Faruki","year":"2008","journal-title":"Per Med"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100136_bib129","doi-asserted-by":"crossref","first-page":"693","DOI":"10.3390\/biomedicines10030693","article-title":"Proteomic profiling and T cell receptor usage of abacavir susceptible subjects","volume":"10","author":"Gall","year":"2022","journal-title":"Biomedicines"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100136_bib130","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.humimm.2020.02.011","article-title":"New genetic predictors for abacavir tolerance in HLA-B\u221757:01 positive individuals","volume":"81","author":"Pavlos","year":"2020","journal-title":"Hum Immunol"},{"key":"10.1016\/j.pharmr.2026.100136_bib131","series-title":"Ziagen Prescribing Information","year":"2008"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100136_bib132","doi-asserted-by":"crossref","first-page":"314","DOI":"10.2174\/138920212800793311","article-title":"The pharmacogenomic HLA biomarker associated to adverse abacavir reactions: comparative analysis of different genotyping methods","volume":"13","author":"Stocchi","year":"2012","journal-title":"Curr Genomics"},{"key":"10.1016\/j.pharmr.2026.100136_bib133","series-title":"Medical Genetics Summaries","article-title":"Abacavir therapy and HLA-B\u221757:01 genotype","author":"Dean","year":"2012"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100136_bib134","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12981-019-0217-3","article-title":"HLA-B\u221757:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA\u00ae observational database: a cohort study","volume":"16","author":"Mounzer","year":"2019","journal-title":"AIDS Res Ther"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100136_bib135","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.pbj.2016.12.004","article-title":"Prevalence of abacavir-associated hypersensitivity syndrome and HLA-b\u22175701 allele in a Portuguese HIV-positive population","volume":"2","author":"Carolino","year":"2017","journal-title":"Porto Biomed J"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100136_bib136","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/s12879-017-2331-y","article-title":"HLA-B\u221757:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B\u221757:01-negative subjects","volume":"17","author":"Small","year":"2017","journal-title":"BMC Infect Dis"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100136_bib137","article-title":"Prevalence of the HLA-b\u22175701 allele and abacavir hypersensitivity in Saudi HIV patients: a multicenter study","volume":"15","author":"Alsaeed","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.pharmr.2026.100136_bib138","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.891838","article-title":"Distribution of HLA-B alleles and haplotypes in Qatari: recommendation for establishing pharmacogenomic markers screening for drug hypersensitivity","volume":"13","author":"Dashti","year":"2022","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100136_bib139","first-page":"48","article-title":"Prevalence of HLA-b\u22175701 and its relationship with abacavir hypersensitivity reaction in Iranian HIV-infected patients","volume":"15","author":"Baniasadi","year":"2016","journal-title":"Tanaffos"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100136_bib140","doi-asserted-by":"crossref","first-page":"29","DOI":"10.5578\/mb.20249903","article-title":"Distribution of the prevalence of human leukocyte antigen (HLA)-B\u221757:01 positivity in HIV-1 infected individuals and its effects on treatment: T\u00fcrkiye Map-Buhasder Working Group. Article in Turkish","volume":"58","author":"B\u00fcy\u00fcktuna","year":"2024","journal-title":"Mikrobiyol Bul"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100136_bib141","doi-asserted-by":"crossref","first-page":"254","DOI":"10.2174\/1570162X21666230731145350","article-title":"The prevalence of HLA-b\u221757 serotype associated with hypersensitivity reactions in the treatment of HIV infection in the Turkish population","volume":"21","author":"Kizmaz","year":"2023","journal-title":"Curr HIV Res"},{"key":"10.1016\/j.pharmr.2026.100136_bib142","series-title":"Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach","year":"2016"},{"key":"10.1016\/j.pharmr.2026.100136_bib143","series-title":"Consolidated Guidelines on HIV Prevention, Testing, Treatment, Service Delivery and Monitoring: Recommendations for a Public Health Approach","year":"2021"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100136_bib144","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1136\/ejhpharm-2020-002374","article-title":"Discontinuation due to neuropsychiatric adverse events with efavirenz- and dolutegravir-based antiretroviral therapy: a comparative real-life study","volume":"29","author":"Fern\u00e1ndez-Bargiela","year":"2022","journal-title":"Eur J Hosp Pharm"},{"issue":"20","key":"10.1016\/j.pharmr.2026.100136_bib145","first-page":"10729","article-title":"Efavirenz as a psychotropic drug","volume":"24","author":"Zareifopoulos","year":"2020","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100136_bib146","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/QAI.0000000000001451","article-title":"Brief report: late efavirenz-induced ataxia and encephalopathy: a case series","volume":"75","author":"Variava","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100136_bib147","doi-asserted-by":"crossref","first-page":"876","DOI":"10.7196\/SAMJnew.8780","article-title":"Efavirenz as a cause of ataxia in children","volume":"105","author":"Hauptfleisch","year":"2015","journal-title":"S Afr Med J"},{"key":"10.1016\/j.pharmr.2026.100136_bib148","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12879-016-1381-x","article-title":"Case report: severe central nervous system manifestations associated with aberrant efavirenz metabolism in children: the role of CYP2B6 genetic variation","volume":"16","author":"Pinillos","year":"2016","journal-title":"BMC Infect Dis"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100136_bib149","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.4102\/sajhivmed.v24i1.1439","article-title":"Late-onset efavirenz toxicity: a descriptive study from Pretoria, South Africa","volume":"24","author":"Munsami","year":"2023","journal-title":"South Afr J HIV Med"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100136_bib150","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1124\/dmd.119.086348","article-title":"Efavirenz metabolism: influence of polymorphic CYP2B6 variants and stereochemistry","volume":"47","author":"Wang","year":"2019","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100136_bib151","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/00002030-200101050-00011","article-title":"Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients","volume":"15","author":"Marzolini","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.pharmr.2026.100136_bib152","article-title":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury","year":"2012","journal-title":"National Institute of Diabetes and Digestive and Kidney Diseases (US)"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100136_bib153","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.3390\/cells10051263","article-title":"Hepatotoxicity of contemporary antiretroviral drugs: a review and evaluation of published clinical data","volume":"10","author":"Otto","year":"2021","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100136_bib154","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/cpt.1477","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2B6 and efavirenz-containing antiretroviral therapy","volume":"106","author":"Desta","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.pharmr.2026.100136_bib155","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1146\/annurev-pharmtox-021320-111248","article-title":"Pharmacogenomics of antiretroviral drug metabolism and transport","volume":"61","author":"Yu","year":"2021","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100136_bib156","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/cpt.2166","article-title":"PharmVar GeneFocus: CYP2B6","volume":"110","author":"Desta","year":"2021","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100136_bib157","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1086\/499369","article-title":"Efavirenz and CYP2B6 polymorphism: implications for drug toxicity and resistance","volume":"42","author":"Nolan","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100136_bib158","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2217\/14622416.8.7.743","article-title":"Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance","volume":"8","author":"Zanger","year":"2007","journal-title":"Pharmacogenomics"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100136_bib159","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01213011-200501000-00001","article-title":"Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients","volume":"15","author":"Rotger","year":"2005","journal-title":"Pharmacogenet Genomics"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100136_bib160","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1124\/jpet.103.049601","article-title":"The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV\/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity","volume":"306","author":"Ward","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100136_bib161","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1124\/jpet.106.102525","article-title":"Metabolism of efavirenz and 8-hydroxyefavirenz by P450 2B6 leads to inactivation by two distinct mechanisms","volume":"318","author":"Bumpus","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100136_bib162","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2217\/14622416.8.6.547","article-title":"Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro","volume":"8","author":"Desta","year":"2007","journal-title":"Pharmacogenomics"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100136_bib163","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1124\/dmd.109.031393","article-title":"Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation","volume":"38","author":"Ogburn","year":"2010","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100136_bib164","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1124\/dmd.112.049601","article-title":"Compartmentalization and antiviral effect of efavirenz metabolites in blood plasma, seminal plasma, and cerebrospinal fluid","volume":"41","author":"Avery","year":"2013","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100136_bib165","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1124\/jpet.112.195701","article-title":"Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz","volume":"343","author":"Tovar-y-Romo","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100136_bib166","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1124\/dmd.109.027706","article-title":"Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine","volume":"37","author":"B\u00e9langer","year":"2009","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100136_bib167","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/FPC.0b013e328328d577","article-title":"In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function","volume":"19","author":"di Iulio","year":"2009","journal-title":"Pharmacogenet Genomics"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100136_bib168","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1128\/AAC.41.5.1099","article-title":"Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89","volume":"41","author":"Faletto","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100136_bib170","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e28952","article-title":"Genetic variants, haplotype determination, and function of novel alleles of CYP2B6 in a Han Chinese population","volume":"10","author":"Zhang","year":"2024","journal-title":"Heliyon"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100136_bib171","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/cpt.70115","article-title":"Long-read sequencing enhances pharmacogenomic profiling by resolving complex haplotypes, novel star alleles, and structural variants","volume":"119","author":"Samarasinghe","year":"2025","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100136_bib172","article-title":"Sudden cardiac death and sudden cardiac arrest in patients with human immunodeficiency virus: a systematic review","volume":"13","author":"Abdelazeem","year":"2021","journal-title":"Cureus"},{"issue":"21","key":"10.1016\/j.pharmr.2026.100136_bib173","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1016\/j.jacc.2012.02.024","article-title":"Sudden cardiac death in patients with human immunodeficiency virus infection","volume":"59","author":"Tseng","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100136_bib174","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1468-1293.2012.00996.x","article-title":"Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis","volume":"13","author":"Islam","year":"2012","journal-title":"HIV Med"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100136_bib175","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1345\/aph.1A454","article-title":"Efavirenz-associated QT prolongation and torsade de pointes arrhythmia","volume":"36","author":"Castillo","year":"2002","journal-title":"Ann Pharmacother"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100136_bib176","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1002\/clc.23705","article-title":"Association between exposure to efavirenz and substrates of dysrhythmia in HIV-infected young adults","volume":"44","author":"Hosseini","year":"2021","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.pharmr.2026.100136_bib177","series-title":"SUSTIVA (efavirenz) prescribing onformation","year":"2017"},{"key":"10.1016\/j.pharmr.2026.100136_bib178","series-title":"HIV","year":"2024"},{"issue":"18","key":"10.1016\/j.pharmr.2026.100136_bib179","first-page":"2391","article-title":"Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study","volume":"18","author":"Haas","year":"2004","journal-title":"AIDS"},{"issue":"16","key":"10.1016\/j.pharmr.2026.100136_bib180","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1097\/QAD.0b013e3283319908","article-title":"CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients","volume":"23","author":"Kwara","year":"2009","journal-title":"AIDS"},{"key":"10.1016\/j.pharmr.2026.100136_bib181","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/1471-2350-13-112","article-title":"PXR and CAR single nucleotide polymorphisms influence plasma efavirenz levels in South African HIV\/AIDS patients","volume":"13","author":"Swart","year":"2012","journal-title":"BMC Med Genet"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100136_bib182","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1086\/528861","article-title":"Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort study","volume":"46","author":"Wit","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100136_bib183","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.4102\/sajhivmed.v22i1.1182","article-title":"Nevirapine-induced Stevens-Johnson syndrome in children living with HIV in South Africa","volume":"22","author":"du Toit","year":"2021","journal-title":"South Afr J HIV Med"},{"key":"10.1016\/j.pharmr.2026.100136_bib184","series-title":"Viramune (nevirapine) prescribing information","year":"2011"},{"key":"10.1016\/j.pharmr.2026.100136_bib185","author":"Klein"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100136_bib186","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.3390\/cells10071687","article-title":"NNRTI and liver damage: evidence of their association and the mechanisms involved","volume":"10","author":"Benedicto","year":"2021","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100136_bib187","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3109\/03602532.2014.982864","article-title":"Pharmacogenetics of CYP2B6, CYP2A6 and UGT2B7 in HIV treatment in African populations: focus on efavirenz and nevirapine","volume":"47","author":"\u010coli\u0107","year":"2015","journal-title":"Drug Metab Rev"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100136_bib188","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0090-9556(24)15239-7","article-title":"Disposition and biotransformation of the antiretroviral drug nevirapine in humans","volume":"27","author":"Riska","year":"1999","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100136_bib189","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-74506-x","article-title":"Effects of CYP2B6 polymorphisms on plasma nevirapine concentrations: a systematic review and meta-analysis","volume":"10","author":"Yoon","year":"2020","journal-title":"Sci Rep"},{"issue":"9300","key":"10.1016\/j.pharmr.2026.100136_bib190","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0140-6736(02)07276-8","article-title":"Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study","volume":"359","author":"Fellay","year":"2002","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100136_bib191","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1086\/507097","article-title":"Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration","volume":"43","author":"Haas","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.pharmr.2026.100136_bib192","article-title":"Genetics of severe cutaneous adverse reactions","volume":"8","author":"Yang","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100136_bib193","article-title":"A bioinformatic approach to identify pathogenic variants for Stevens-Johnson syndrome","volume":"21","author":"Ma'ruf","year":"2023","journal-title":"Genomics Inform"},{"key":"10.1016\/j.pharmr.2026.100136_bib194","series-title":"Atazanavir. StatPearls","author":"Choi","year":"2024"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100136_bib195","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/FPC.0000000000000331","article-title":"PharmGKB summary: atazanavir pathway, pharmacokinetics\/pharmacodynamics","volume":"28","author":"Alvarellos","year":"2018","journal-title":"Pharmacogenet Genomics"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100136_bib196","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1592\/phco.24.17.1732.52347","article-title":"Atazanavir for the treatment of human immunodeficiency virus infection","volume":"24","author":"Busti","year":"2004","journal-title":"Pharmacotherapy"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100136_bib197","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.3390\/ijms22042114","volume":"22","author":"Akita","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100136_bib198","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/clpt.2012.137","article-title":"Effect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patients","volume":"92","author":"Savic","year":"2012","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100136_bib199","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/17512433.2022.2000858","article-title":"Pharmacogenetics-based population pharmacokinetic analysis for dose optimization of ritonavir-boosted atazanavir in Thai adult HIV-infected patients","volume":"15","author":"Singkham","year":"2022","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100136_bib200","doi-asserted-by":"crossref","first-page":"5242","DOI":"10.1128\/AAC.00781-10","article-title":"Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance","volume":"54","author":"Schipani","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100136_bib201","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1089\/aid.2011.0378","article-title":"A population pharmacokinetic-pharmacogenetic analysis of atazanavir","volume":"28","author":"Kile","year":"2012","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.pharmr.2026.100136_bib204","author":"Hepatitis"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100136_bib205","doi-asserted-by":"crossref","first-page":"e1254","DOI":"10.1093\/infdis\/jiae253","article-title":"Identification of 2 novel subtypes of hepatitis C virus Genotype 8 and a potential new genotype successfully treated with direct acting antivirals","volume":"230","author":"Mbisa","year":"2024","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100136_bib206","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hep.27259","article-title":"Global distribution and prevalence of hepatitis C virus genotypes","volume":"61","author":"Messina","year":"2015","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100136_bib207","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1128\/JCM.02831-14","article-title":"Hepatitis C virus genotype 7, a new genotype originating from central Africa","volume":"53","author":"Murphy","year":"2015","journal-title":"J Clin Microbiol"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100136_bib208","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1093\/infdis\/jiy401","article-title":"Identification of a novel hepatitis C virus genotype from Punjab, India: expanding classification of hepatitis C virus into 8 genotypes","volume":"218","author":"Borgia","year":"2018","journal-title":"J Infect Dis"},{"issue":"9286","key":"10.1016\/j.pharmr.2026.100136_bib209","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"PEGinterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.pharmr.2026.100136_bib210","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1001\/jama.2012.144878","article-title":"Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis","volume":"308","author":"van der Meer","year":"2012","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100136_bib211","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/tpj.2015.28","article-title":"Interleukin 28B polymorphisms as predictors of sustained virological response in chronic hepatitis C: systematic review and meta-analysis","volume":"16","author":"Cariani","year":"2016","journal-title":"Pharmacogenomics J"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100136_bib212","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1111\/jvh.13162","article-title":"Adjuvant ribavirin and longer direct-acting antiviral treatment duration improve sustained virological response among hepatitis C patients at risk of treatment failure","volume":"26","author":"Lu","year":"2019","journal-title":"J Viral Hepat"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100136_bib213","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.coi.2011.07.007","article-title":"IFN-\u03bbs","volume":"23","author":"Kotenko","year":"2011","journal-title":"Curr Opin Immunol"},{"issue":"7262","key":"10.1016\/j.pharmr.2026.100136_bib214","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature08309","article-title":"Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance","volume":"461","author":"Ge","year":"2009","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100136_bib215","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/ng.447","article-title":"IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy","volume":"41","author":"Suppiah","year":"2009","journal-title":"Nat Genet"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100136_bib216","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/ng.449","article-title":"Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C","volume":"41","author":"Tanaka","year":"2009","journal-title":"Nat Genet"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100136_bib217","doi-asserted-by":"crossref","first-page":"807","DOI":"10.12998\/wjcc.v3.i9.807","article-title":"Role of genetic polymorphisms in hepatitis C virus chronic infection","volume":"3","author":"Coppola","year":"2015","journal-title":"World J Clin Cases"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100136_bib218","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/ng.2521","article-title":"A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus","volume":"45","author":"Prokunina-Olsson","year":"2013","journal-title":"Nat Genet"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100136_bib219","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.jhep.2015.06.035","article-title":"Comparison of functional variants in IFNL4 and IFNL3 for association with HCV clearance","volume":"63","author":"O'Brien","year":"2015","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100136_bib220","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1053\/j.gastro.2010.04.049","article-title":"Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C","volume":"139","author":"Honda","year":"2010","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100136_bib221","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1002\/hep.30195","article-title":"Revisiting the paradox of interferon-stimulated gene expression as a predictor of hepatitis C virus treatment response, a decade later","volume":"68","author":"Golden-Mason","year":"2018","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100136_bib222","doi-asserted-by":"crossref","first-page":"3808","DOI":"10.4049\/jimmunol.1700807","article-title":"IFN-\u03bb4 attenuates antiviral responses by enhancing negative regulation of IFN signaling","volume":"199","author":"Obajemu","year":"2017","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmr.2026.100136_bib223","series-title":"PEGINTRON\u00ae (peginterferon alfa-2b) [prescribing information]","year":"2019"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100136_bib224","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/clpt.2013.203","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-\u03b1-based regimens","volume":"95","author":"Muir","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.pharmr.2026.100136_bib225","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciad319","article-title":"Guidance Panel. Hepatitis C guidance 2023 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection","author":"Bhattacharya","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100136_bib226","doi-asserted-by":"crossref","first-page":"701","DOI":"10.2217\/pgs-2018-0009","article-title":"Vitamin D pathway gene polymorphisms affecting daclatasvir plasma concentration at 2 weeks and 1 month of therapy","volume":"19","author":"Cusato","year":"2018","journal-title":"Pharmacogenomics"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100136_bib227","doi-asserted-by":"crossref","first-page":"171","DOI":"10.18433\/J3DK6T","article-title":"Intracellular and plasma trough concentration and pharmacogenetics of telaprevir","volume":"18","author":"Cusato","year":"2015","journal-title":"J Pharm Pharm Sci"},{"issue":"7287","key":"10.1016\/j.pharmr.2026.100136_bib228","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nature08825","article-title":"ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C","volume":"464","author":"Fellay","year":"2010","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100136_bib229","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1053\/j.gastro.2010.06.016","article-title":"Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction","volume":"139","author":"Thompson","year":"2010","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100136_bib230","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/hep.24068","article-title":"Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2\/3 but do not decrease dose reductions of RBV or increase SVR","volume":"53","author":"Thompson","year":"2011","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100136_bib231","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1111\/hepr.12681","article-title":"Effects of ITPA polymorphism on decrease of hemoglobin during simeprevir, peg-interferon, and ribavirin combination treatment for chronic hepatitis C","volume":"46","author":"Morio","year":"2016","journal-title":"Hepatol Res"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100136_bib232","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/FPC.0000000000000123","article-title":"VDR gene polymorphisms impact on anemia at 2 weeks of anti-HCV therapy: a possible mechanism for early RBV-induced anemia","volume":"25","author":"Cusato","year":"2015","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.pharmr.2026.100136_bib233","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1186\/s12967-015-0682-y","article-title":"Relationship between ITPA polymorphisms and hemolytic anemia in HCV-infected patients after ribavirin-based therapy: a meta-analysis","volume":"13","author":"Pineda-Tenor","year":"2015","journal-title":"J Transl Med"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100136_bib234","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1111\/jcpt.13232","article-title":"Association between inosine triphosphatase rs1127354 polymorphisms and ribavirin-induced anaemia and outcome in hepatitis C virus-infected patients: a meta-analysis","volume":"45","author":"Ma","year":"2020","journal-title":"J Clin Pharm Ther"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100136_bib235","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.3390\/ph16111596","article-title":"Impact of pharmacogenomics in clinical practice","volume":"16","author":"Principi","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.pharmr.2026.100136_bib236","first-page":"261","article-title":"Pharmacogenomic response of inhaled corticosteroids for the treatment of asthma: considerations for therapy","volume":"13","author":"Cazzola","year":"2020","journal-title":"Pharmgenomics Pers Med"},{"key":"10.1016\/j.pharmr.2026.100136_bib237","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.835136","article-title":"Pharmacogenetics and precision medicine approaches for the improvement of COVID-19 therapies","volume":"13","author":"Biswas","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.pharmr.2026.100136_bib238","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2022.102172","article-title":"Considerations into pharmacogenomics of COVID-19 pharmacotherapy: hope, hype and reality","volume":"77","author":"Al-Taie","year":"2022","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.pharmr.2026.100136_bib239","article-title":"Nirmatrelvir\/Ritonavir","author":"Lam","year":"2024","journal-title":"StatPearls"},{"issue":"6575","key":"10.1016\/j.pharmr.2026.100136_bib240","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100136_bib244","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jsps.2022.01.021","article-title":"Incidence and risk factors of adverse drug reactions in patients with coronavirus disease 2019: a pharmacovigilance experience utilizing an ADR trigger tool","volume":"30","author":"Alshehail","year":"2022","journal-title":"Saudi Pharm J"},{"key":"10.1016\/j.pharmr.2026.100136_bib245","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.602841","article-title":"Incidence of suspected serious adverse drug reactions in corona virus Disease-19 patients detected by a pharmacovigilance program by laboratory signals in a Tertiary Hospital in Spain: cautionary data","volume":"11","author":"Ram\u00edrez","year":"2020","journal-title":"Front Pharmacol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100136_bib246","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/CCM.0000000000005756","article-title":"Outcomes and adverse effects of baricitinib versus tocilizumab in the management of severe COVID-19","volume":"51","author":"Peterson","year":"2023","journal-title":"Crit Care Med"},{"issue":"7921","key":"10.1016\/j.pharmr.2026.100136_bib247","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1038\/s41586-022-04826-7","article-title":"A first update on mapping the human genetic architecture of COVID-19","volume":"608","year":"2022","journal-title":"Nature"},{"issue":"16","key":"10.1016\/j.pharmr.2026.100136_bib248","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1056\/NEJMoa2020283","article-title":"Genomewide association study of severe Covid-19 with respiratory failure","volume":"383","author":"Ellinghaus","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmr.2026.100136_bib249","article-title":"Mapping the human genetic architecture of COVID-19 by worldwide meta-analysis","author":"Ganna","year":"2021","journal-title":"medRxiv"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100136_bib250","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030052","article-title":"Associations among race\/ethnicity, ApoC-III genotypes, and lipids in HIV-1-infected individuals on antiretroviral therapy","volume":"3","author":"Foulkes","year":"2006","journal-title":"PLoS Med"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100136_bib251","doi-asserted-by":"crossref","first-page":"655","DOI":"10.3390\/ph14070655","article-title":"ADME and pharmacokinetic properties of remdesivir: its drug interaction potential","volume":"14","author":"Deb","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100136_bib252","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1111\/cts.13313","article-title":"Pharmacogenetic variants and risk of remdesivir-associated liver enzyme elevations in Million Veteran Program participants hospitalized with COVID-19","volume":"15","author":"Tuteja","year":"2022","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.pharmr.2026.100136_bib253","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1418567","article-title":"Genetic variability in the glucocorticoid pathway and treatment outcomes in hospitalized patients with COVID-19: a pilot study","volume":"15","author":"\u0160tampar","year":"2024","journal-title":"Front Pharmacol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100136_bib254","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1136\/annrheumdis-2021-220578","article-title":"Severe delayed hypersensitivity reactions to IL-1 and IL-6 inhibitors link to common HLA-DRB1\u221715 alleles","volume":"81","author":"Saper","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.pharmr.2026.100136_bib255","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.phrs.2016.06.016","article-title":"Genetic and clinical biomarkers of tocilizumab response in patients with rheumatoid arthritis","volume":"111","author":"Maldonado-Montoro","year":"2016","journal-title":"Pharmacol Res"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100136_bib256","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/jcph.1341","article-title":"FCGR2A\/FCGR3A gene polymorphisms and clinical variables as predictors of response to tocilizumab and rituximab in patients with rheumatoid arthritis","volume":"59","author":"Jim\u00e9nez Morales","year":"2019","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100136_bib257","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/tpj.2016.88","article-title":"Influence of IL6R gene polymorphisms in the effectiveness to treatment with tocilizumab in rheumatoid arthritis","volume":"18","author":"Maldonado-Montoro","year":"2018","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.pharmr.2026.100136_bib258","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.113769","article-title":"Associations of genetic polymorphisms with clinical response to tocilizumab in Chinese rheumatoid arthritis patients","volume":"146","author":"Qin","year":"2025","journal-title":"Int Immunopharmacol"},{"issue":"23","key":"10.1016\/j.pharmr.2026.100136_bib259","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2022.9846","article-title":"Baricitinib is first approved COVID-19 immunomodulatory treatment","volume":"327","author":"Rubin","year":"2022","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100136_bib261","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1038\/s41375-023-01979-w","article-title":"The JAK1\/2 inhibitor Ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trial","volume":"37","author":"Hammersen","year":"2023","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100136_bib263","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41525-020-00143-y","article-title":"Pharmacogenomics of COVID-19 therapies","volume":"5","author":"Takahashi","year":"2020","journal-title":"npj Genom Med"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100136_bib265","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3390\/futurepharmacol4010008","article-title":"Pharmacokinetics profile and genetics of double antiviral therapy with remdesivir and Nirmatrelvir\/Ritonavir for prolonged COVID-19 in patients treated with rituximab: a real-life study and literature review","volume":"4","author":"De Benedetto","year":"2024","journal-title":"Future Pharmacol"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100136_bib266","first-page":"23","article-title":"Long COVID and wavering incidence of pulmonary embolism: a systematic review","volume":"13","author":"Shah","year":"2023","journal-title":"J Community Hosp Intern Med Perspect"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100136_bib267","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3325\/cmj.2022.63.287","article-title":"The role of direct oral anticoagulants in the era of COVID-19: are antiviral therapy and pharmacogenetics limiting factors?","volume":"63","author":"Rogulji\u0107","year":"2022","journal-title":"Croat Med J"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100136_bib268","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/FPC.0000000000000465","article-title":"PharmGKB summary: heparin-induced thrombocytopenia pathway, adverse drug reaction","volume":"32","author":"Miller","year":"2022","journal-title":"Pharmacogenet Genomics"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100136_bib269","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/cpt.668","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for pharmacogenetics-guided warfarin dosing: 2017 update","volume":"102","author":"Johnson","year":"2017","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100136_bib270","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/s41397-020-0151-8","article-title":"Association study of genetic polymorphisms in proteins involved in oseltamivir transport, metabolism, and interactions with adverse reactions in Mexican patients with acute respiratory diseases","volume":"20","author":"Berm\u00fadez de Le\u00f3n","year":"2020","journal-title":"Pharmacogenomics J"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100136_bib271","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0176320","article-title":"The novel carboxylesterase 1 variant c.662A>G may decrease the bioactivation of oseltamivir in humans","volume":"12","author":"Oh","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmr.2026.100136_bib272","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.phrs.2016.07.012","article-title":"Multidrug resistance-associated protein 4 (MRP4) controls ganciclovir intracellular accumulation and contributes to ganciclovir-induced neutropenia in renal transplant patients","volume":"111","author":"Billat","year":"2016","journal-title":"Pharmacol Res"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100136_bib273","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/jcph.1420","article-title":"Pharmacogenetic analysis of OATP1B1, UGT1A1, and BCRP variants in relation to the pharmacokinetics of Letermovir in previously conducted clinical studies","volume":"59","author":"Kobie","year":"2019","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100136_bib275","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/ja.2017.62","article-title":"A brief history of antibiotics and select advances in their synthesis","volume":"71","author":"Nicolaou","year":"2018","journal-title":"J Antibiot (Tokyo)"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100136_bib276","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jsps.2013.06.004","article-title":"A prospective study on Adverse Drug Reactions of antibiotics in a tertiary care hospital","volume":"22","author":"Shamna","year":"2014","journal-title":"Saudi Pharm J"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100136_bib277","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.298","article-title":"Antibiotic-associated suspected adverse drug reactions among hospitalized patients in Uganda: a prospective cohort study","volume":"5","author":"Kiguba","year":"2017","journal-title":"Pharmacol Res Perspect"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100136_bib278","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1001\/jamainternmed.2017.1938","article-title":"Association of adverse events with antibiotic use in hospitalized patients","volume":"177","author":"Tamma","year":"2017","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.pharmr.2026.100136_bib279","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1186\/s12879-015-1303-3","article-title":"The prevalence and impact of antimicrobial allergies and adverse drug reactions at an Australian tertiary centre","volume":"15","author":"Trubiano","year":"2015","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.pharmr.2026.100136_bib280","doi-asserted-by":"crossref","DOI":"10.1051\/e3sconf\/202131901048","article-title":"Adverse drug reactions of anti-infective drugs for systemic use in Morocco: pharmaco-epidemiological study 2008-2016","volume":"319","author":"Kharbouch","year":"2021","journal-title":"E3S Web Conf"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100136_bib281","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.jsps.2022.03.018","article-title":"The evaluation of adverse drug reactions in Saudi Arabia: a retrospective observational study","volume":"30","author":"Alenzi","year":"2022","journal-title":"Saudi Pharm J"},{"key":"10.1016\/j.pharmr.2026.100136_bib282","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.vascn.2016.04.011","article-title":"Frequency, types, severity, preventability and costs of Adverse Drug Reactions at a tertiary care hospital","volume":"81","author":"Geer","year":"2016","journal-title":"J Pharmacol Toxicol Methods"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100136_bib283","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/cpt.2309","article-title":"Clinical pharmacogenetics implementation consortium guideline for the use of aminoglycosides based on MT-RNR1 genotype","volume":"111","author":"McDermott","year":"2022","journal-title":"Clin Pharmacol Ther"},{"issue":"17","key":"10.1016\/j.pharmr.2026.100136_bib284","doi-asserted-by":"crossref","first-page":"5975","DOI":"10.3390\/ijms21175975","article-title":"Pharmacogenomics of antibiotics","volume":"21","author":"Stocco","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100136_bib285","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0068111","article-title":"HLA alleles influence the clinical signature of amoxicillin-clavulanate hepatotoxicity","volume":"8","author":"Stephens","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100136_bib286","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1053\/j.gastro.2011.04.001","article-title":"Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles","volume":"141","author":"Lucena","year":"2011","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100136_bib287","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1053\/j.gastro.2019.01.034","article-title":"A missense variant in PTPN22 is a risk factor for drug-induced liver injury","volume":"156","author":"Cirulli","year":"2019","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100136_bib288","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1053\/j.gastro.2022.11.036","article-title":"Identification of reduced ERAP2 expression and a novel HLA allele as components of a risk score for susceptibility to liver injury due to amoxicillin-clavulanate","volume":"164","author":"Nicoletti","year":"2023","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100136_bib289","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/hep.26077","article-title":"Human leukocyte antigen (HLA)-B\u221757:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury","volume":"57","author":"Monshi","year":"2013","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100136_bib290","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1002\/hep.23549","article-title":"A role for the pregnane X receptor in flucloxacillin-induced liver injury","volume":"51","author":"Andrews","year":"2010","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100136_bib291","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1002\/jcph.1266","article-title":"Effect of ABCC2 and ABCG2 gene polymorphisms and CSF-to-Serum albumin ratio on ceftriaxone plasma and cerebrospinal fluid concentrations","volume":"58","author":"Allegra","year":"2018","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100136_bib292","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/cpt.1915","article-title":"Genetic association of co-trimoxazole-induced severe cutaneous adverse reactions is phenotype-specific: HLA class I genotypes and haplotypes","volume":"108","author":"Sukasem","year":"2020","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100136_bib293","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/FPC.0000000000000153","article-title":"Candidate HLA genes for prediction of co-trimoxazole-induced severe cutaneous reactions","volume":"25","author":"Kongpan","year":"2015","journal-title":"Pharmacogenet Genomics"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100136_bib294","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/j.jaci.2020.08.003","article-title":"Whole genome sequencing identifies genetic variants associated with co-trimoxazole hypersensitivity in Asians","volume":"147","author":"Wang","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100136_bib295","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/FPC.0000000000000441","article-title":"Sulfamethoxazole-trimethoprim-induced liver injury and genetic polymorphisms of NAT2 and CYP2C9 in Taiwan","volume":"31","author":"Huang","year":"2021","journal-title":"Pharmacogenet Genomics"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100136_bib296","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/s41397-022-00266-8","article-title":"HLA-B\u221707:02 and HLA-C\u221707:02 are associated with trimethoprim-sulfamethoxazole respiratory failure","volume":"22","author":"Goldman","year":"2022","journal-title":"Pharmacogenomics J"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100136_bib297","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/hep.31258","article-title":"Human leukocyte antigen B\u221714:01 and B\u221735:01 are associated with trimethoprim-sulfamethoxazole induced liver injury","volume":"73","author":"Li","year":"2021","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100136_bib298","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S1734-1140(09)70140-9","article-title":"Influence of ABCB1 gene polymorphisms on the pharmacokinetics of azithromycin among healthy Chinese Han ethnic subjects","volume":"61","author":"He","year":"2009","journal-title":"Pharmacol Rep"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100136_bib299","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/clpt.2011.25","article-title":"Effect of ABCC2 (MRP2) transport function on erythromycin metabolism","volume":"89","author":"Franke","year":"2011","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100136_bib300","first-page":"81","article-title":"Determining the relation between N-acetyltransferase-2 acetylator phenotype and antituberculosis drug induced hepatitis by molecular biologic tests","volume":"56","author":"Bozok Cetinta\u015f","year":"2008","journal-title":"Tuberk Toraks"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100136_bib301","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1440-1681.2012.05713.x","article-title":"NAT2 and CYP2E1 polymorphisms associated with antituberculosis drug-induced hepatotoxicity in Chinese patients","volume":"39","author":"An","year":"2012","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100136_bib302","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3390\/antibiotics12030425","article-title":"Relevance of pharmacogenomics to the safe use of antimicrobials","volume":"12","author":"Daly","year":"2023","journal-title":"Antibiotics (Basel)"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100136_bib303","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a027029","article-title":"Aminoglycosides: an overview","volume":"6","author":"Krause","year":"2016","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100136_bib304","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3390\/ph17030331","article-title":"Genetic variations and antibiotic-related adverse events","volume":"17","author":"Principi","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100136_bib305","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1128\/AAC.44.12.3249-3256.2000","article-title":"Aminoglycosides: perspectives on mechanisms of action and resistance and strategies to counter resistance","volume":"44","author":"Kotra","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100136_bib306","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/cpt.603","article-title":"Drug-induced ototoxicity: mechanisms, Pharmacogenetics, and protective strategies","volume":"101","author":"Lanvers-Kaminsky","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.pharmr.2026.100136_bib307","series-title":"Aminoglycosides","author":"Block","year":"2025"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100136_bib308","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2174\/138161207779313731","article-title":"Aminoglycoside-induced ototoxicity","volume":"13","author":"Selimoglu","year":"2007","journal-title":"Curr Pharm Des"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100136_bib309","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1007\/s12325-023-02436-x","article-title":"Aminoglycoside-related nephrotoxicity and ototoxicity in clinical practice: a review of pathophysiological mechanism and treatment options","volume":"40","author":"Le","year":"2023","journal-title":"Adv Ther"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100136_bib310","doi-asserted-by":"crossref","first-page":"E52","DOI":"10.1503\/cmaj.140339","article-title":"Aminoglycoside-induced ototoxicity","volume":"187","author":"Leis","year":"2015","journal-title":"CMAJ"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100136_bib311","doi-asserted-by":"crossref","DOI":"10.1093\/jacamr\/dlab184","article-title":"Aminoglycoside- and glycopeptide-induced ototoxicity in children: a systematic review","volume":"3","author":"Diepstraten","year":"2021","journal-title":"JAC Antimicrob Resist"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100136_bib312","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-21074-x","article-title":"Aminoglycosides use has a risk of acute kidney injury in patients without prior chronic kidney disease","volume":"12","author":"Chou","year":"2022","journal-title":"Sci Rep"},{"issue":"e1","key":"10.1016\/j.pharmr.2026.100136_bib313","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1136\/ejhpharm-2021-002868","article-title":"Detection of subclinical nephrotoxicity induced by aminoglycosides in critically ill elderly patients using trough levels and urinary neutrophil gelatinase-associated lipocalin","volume":"29","author":"Sadeghi","year":"2022","journal-title":"Eur J Hosp Pharm"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100136_bib314","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a033548","article-title":"Aminoglycoside- and cisplatin-induced ototoxicity: mechanisms and otoprotective strategies","volume":"9","author":"Kros","year":"2019","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100136_bib315","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/00020840-200310000-00004","article-title":"Ototoxicity: bioprotective mechanisms","volume":"11","author":"Rybak","year":"2003","journal-title":"Curr Opin Otolaryngol Head Neck Surg"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100136_bib316","doi-asserted-by":"crossref","first-page":"4612","DOI":"10.1128\/AAC.00965-08","article-title":"Interaction of aminoglycosides with human mitochondrial 12S rRNA carrying the deafness-associated mutation","volume":"53","author":"Qian","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100136_bib317","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.3390\/ph16101353","article-title":"Aminoglycosides-related ototoxicity: mechanisms, risk factors, and prevention in pediatric patients","volume":"16","author":"Rivetti","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"issue":"3S","key":"10.1016\/j.pharmr.2026.100136_bib318","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1044\/2021_AJA-21-00006","article-title":"Mechanisms of aminoglycoside- and cisplatin-induced ototoxicity","volume":"30","author":"Steyger","year":"2021","journal-title":"Am J Audiol"},{"key":"10.1016\/j.pharmr.2026.100136_bib319","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1038\/srep04089","article-title":"Species identification through mitochondrial rRNA genetic analysis","volume":"4","author":"Yang","year":"2014","journal-title":"Sci Rep"},{"issue":"16","key":"10.1016\/j.pharmr.2026.100136_bib320","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1016\/S0960-894X(02)00342-6","article-title":"Decoding region bubble size and aminoglycoside antibiotic binding","volume":"12","author":"Ryu","year":"2002","journal-title":"Bioorg Med Chem Lett"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100136_bib321","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1021\/acsinfecdis.6b00176","article-title":"Antimicrobial activity, AME resistance, and A-site binding studies of anthraquinone-neomycin conjugates","volume":"3","author":"Degtyareva","year":"2017","journal-title":"ACS Infect Dis"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100136_bib322","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1001\/jamapediatrics.2022.0187","article-title":"Rapid point-of-care genotyping to avoid aminoglycoside-induced ototoxicity in neonatal intensive care","volume":"176","author":"McDermott","year":"2022","journal-title":"JAMA Pediatr"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100136_bib323","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a025247","article-title":"\u03b2-lactams and \u03b2-lactamase Inhibitors: an Overview","volume":"6","author":"Bush","year":"2016","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.pharmr.2026.100136_bib324","series-title":"Beta-Lactam Antibiotics","author":"Pandey","year":"2025"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100136_bib325","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1016\/j.jaci.2020.10.004","article-title":"Beta-lactam-induced immediate hypersensitivity reactions: a genome-wide association study of a deeply phenotyped cohort","volume":"147","author":"Nicoletti","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100136_bib326","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.jaip.2018.11.023","article-title":"Drug hypersensitivity reactions documented in electronic health records within a large health system","volume":"7","author":"Wong","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.pharmr.2026.100136_bib327","series-title":"Amoxicillin","author":"Akhavan","year":"2025"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100136_bib328","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1053\/j.gastro.2008.09.011","article-title":"Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States","volume":"135","author":"Chalasani","year":"2008","journal-title":"Gastroenterology"},{"issue":"13","key":"10.1016\/j.pharmr.2026.100136_bib329","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241310855","article-title":"Advances in idiosyncratic drug-induced liver injury issues: new clinical and mechanistic analysis due to Roussel Uclaf causality assessment method use","volume":"24","author":"Teschke","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100136_bib330","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/toxsci\/kfaa128","article-title":"HLA DRB1\u221715:01-DQB1\u221706:02-restricted human CD4+ T cells are selectively activated with amoxicillin-peptide adducts","volume":"178","author":"Tailor","year":"2020","journal-title":"Toxicol Sci"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100136_bib331","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/ng.379","article-title":"HLA-b\u22175701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin","volume":"41","author":"Daly","year":"2009","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100136_bib332","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/cpt.1375","article-title":"Drug-induced liver injury due to flucloxacillin: relevance of multiple human leukocyte antigen alleles","volume":"106","author":"Nicoletti","year":"2019","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100136_bib335","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3390\/ph15010004","article-title":"Genotyping for HLA risk alleles to prevent drug hypersensitivity reactions: impact analysis","volume":"15","author":"Manson","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100136_bib336","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1021\/tx0002435","article-title":"Indirect cytotoxicity of flucloxacillin toward human biliary epithelium via metabolite formation in hepatocytes","volume":"14","author":"Lakehal","year":"2001","journal-title":"Chem Res Toxicol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100136_bib337","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.livres.2018.12.002","article-title":"Pregnane X receptor in drug-induced liver injury: friend or foe?","volume":"2","author":"Shehu","year":"2018","journal-title":"Liver Res"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100136_bib338","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-78327-w","article-title":"Comparing cefotaxime and ceftriaxone in combating meningitis through nose-to-brain delivery using bio\/chemoinformatics tools","volume":"10","author":"Hathout","year":"2020","journal-title":"Sci Rep"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100136_bib339","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.4103\/1673-5374.272568","article-title":"ABC efflux transporters at blood-central nervous system barriers and their implications for treating spinal cord disorders","volume":"15","author":"Koehn","year":"2020","journal-title":"Neural Regen Res"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100136_bib340","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/fcp.12449","article-title":"Beta-lactam-induced severe neutropenia: a descriptive study","volume":"33","author":"Aster","year":"2019","journal-title":"Fundam Clin Pharmacol"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100136_bib341","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1177\/1060028020975646","article-title":"A review of \u03b2-lactam-associated neutropenia and implications for cross-reactivity","volume":"55","author":"Cimino","year":"2021","journal-title":"Ann Pharmacother"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100136_bib342","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1111\/bcp.15170","article-title":"Acute antibiotically induced neutropenia: a systematic review of case reports","volume":"88","author":"Holz","year":"2022","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100136_bib343","article-title":"Antibiotic-induced neutropenia in patients receiving outpatient parenteral antibiotic therapy: a retrospective cohort study","volume":"67","author":"Lam","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100136_bib344","doi-asserted-by":"crossref","first-page":"F1332","DOI":"10.1152\/ajprenal.00319.2007","article-title":"Organic anion transporter 3 (Oat3\/Slc22a8) knockout mice exhibit altered clearance and distribution of penicillin G","volume":"293","author":"Vanwert","year":"2007","journal-title":"Am J Physiol Renal Physiol"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100136_bib345","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2217\/pgs-2015-0008","article-title":"Pharmacokinetics and pharmacogenomics of \u03b2-lactam-induced neutropenia","volume":"17","author":"Hahn","year":"2016","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.pharmr.2026.100136_bib346","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.877932","article-title":"Antibiotic-induced neutropenia in pediatric patients: new insights from Pharmacoepidemiological analyses and a systematic review","volume":"13","author":"Battini","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.pharmr.2026.100136_bib347","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2147\/DHPS.S347522","article-title":"Clinical manifestations and genetic influences in sulfonamide-induced hypersensitivity","volume":"14","author":"Asyraf","year":"2022","journal-title":"Drug Healthc Patient Saf"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100136_bib348","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s12551-021-00795-9","article-title":"Sulfonamide drugs: structure, antibacterial property, toxicity, and biophysical interactions","volume":"13","author":"Ovung","year":"2021","journal-title":"Biophys Rev"},{"key":"10.1016\/j.pharmr.2026.100136_bib349","series-title":"Trimethoprim Sulfamethoxazole","author":"Tyler","year":"2024"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100136_bib350","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s12016-023-08978-w","article-title":"A comprehensive review of sulfonamide hypersensitivity: implications for clinical practice","volume":"65","author":"Serrano-Arias","year":"2023","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.pharmr.2026.100136_bib351","series-title":"NAT2 Gene. PharmVar: Pharmacogene Variation Consortium","year":"2024"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100136_bib352","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.2217\/pgs.11.88","article-title":"Characterization of genetic variation and natural selection at the arylamine N-acetyltransferase genes in global human populations","volume":"12","author":"Mortensen","year":"2011","journal-title":"Pharmacogenomics"},{"issue":"9\u201310","key":"10.1016\/j.pharmr.2026.100136_bib353","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s002280050551","article-title":"The arylamine N-acetyltransferase (NAT2) polymorphism and the risk of adverse reactions to co-trimoxazole in children","volume":"54","author":"Zieli\u0144ska","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100136_bib354","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/FPC.0000000000000062","article-title":"PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2","volume":"24","author":"McDonagh","year":"2014","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.pharmr.2026.100136_bib355","series-title":"Sulfamethoxazole and Trimethoprim DS","year":"2013"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100136_bib356","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1001\/jamadermatol.2024.0210","article-title":"Human leukocyte antigens and sulfamethoxazole\/cotrimoxazole-induced severe cutaneous adverse reactions: a systematic review and meta-analysis","volume":"160","author":"Wu","year":"2024","journal-title":"JAMA Dermatol"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100136_bib357","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2018-3242","article-title":"Severe acute respiratory failure in healthy adolescents exposed to trimethoprim-sulfamethoxazole","volume":"143","author":"Miller","year":"2019","journal-title":"Pediatrics"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100136_bib358","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.tibs.2018.06.011","article-title":"How macrolide antibiotics work","volume":"43","author":"V\u00e1zquez-Laslop","year":"2018","journal-title":"Trends Biochem Sci"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100136_bib359","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/FPC.0000000000000270","article-title":"PharmGKB summary: macrolide antibiotic pathway, pharmacokinetics\/pharmacodynamics","volume":"27","author":"Fohner","year":"2017","journal-title":"Pharmacogenet Genomics"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100136_bib360","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1124\/dmd.108.022285","article-title":"Involvement of intestinal uptake transporters in the absorption of azithromycin and clarithromycin in the rat","volume":"36","author":"Garver","year":"2008","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100136_bib361","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.idc.2004.04.010","article-title":"Macrolides and ketolides: azithromycin, clarithromycin, telithromycin","volume":"18","author":"Zuckerman","year":"2004","journal-title":"Infect Dis Clin North Am"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100136_bib362","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1128\/AAC.48.3.809-814.2004","article-title":"Possible involvement of the drug transporters P glycoprotein and multidrug resistance-associated protein MRP2 in disposition of azithromycin","volume":"48","author":"Sugie","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100136_bib363","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1139\/cjpp-2019-0569","article-title":"The effect of gender and ABCB1 gene polymorphism on the pharmacokinetics of azithromycin in healthy male and female Pakistani subjects","volume":"98","author":"Nazir","year":"2020","journal-title":"Can J Physiol Pharmacol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100136_bib364","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/clpt.1993.155","article-title":"The influence of dose and ethnic origins on the pharmacokinetics of nifedipine","volume":"54","author":"Ahsan","year":"1993","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100136_bib365","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s40262-014-0209-3","article-title":"Interethnic differences in pharmacokinetics of antibacterials","volume":"54","author":"Tsai","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.pharmr.2026.100136_bib366","series-title":"WHO Consolidated Guidelines on Tuberculosis: Module 4: Treatment - Drug-Susceptible Tuberculosis Treatment","year":"2022"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100136_bib367","doi-asserted-by":"crossref","first-page":"506","DOI":"10.5588\/ijtld.23.0078","article-title":"Clinical standards for the management of adverse effects during treatment for TB","volume":"27","author":"Singh","year":"2023","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.pharmr.2026.100136_bib368","series-title":"Tuberculosis","author":"Tobin","year":"2024"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100136_bib369","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1183\/09031936.96.09102026","article-title":"Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis","volume":"9","author":"Schaberg","year":"1996","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100136_bib370","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jceh.2012.12.001","article-title":"Hepatotoxicity related to anti-tuberculosis drugs: mechanisms and management","volume":"3","author":"Ramappa","year":"2013","journal-title":"J Clin Exp Hepatol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100136_bib371","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1440-1746.2007.05207.x","article-title":"Antituberculosis drug-induced hepatotoxicity: concise up-to-date review","volume":"23","author":"Tostmann","year":"2008","journal-title":"J Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100136_bib372","doi-asserted-by":"crossref","DOI":"10.5409\/wjcp.v14.i2.101875","article-title":"Understanding antituberculosis drug-induced hepatotoxicity: risk factors and effective management strategies in the pediatric population","volume":"14","author":"Semwal","year":"2025","journal-title":"World J Clin Pediatr"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100136_bib373","doi-asserted-by":"crossref","first-page":"839","DOI":"10.2174\/138920007782798216","article-title":"Isoniazid: metabolic aspects and toxicological correlates","volume":"8","author":"Preziosi","year":"2007","journal-title":"Curr Drug Metab"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100136_bib375","doi-asserted-by":"crossref","first-page":"293","DOI":"10.5588\/ijtld.18.0324","article-title":"NAT2 variants and toxicity related to anti-tuberculosis agents: a systematic review and meta-analysis","volume":"23","author":"Richardson","year":"2019","journal-title":"Int J Tuberc Lung Dis"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100136_bib376","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.2217\/pgs.09.66","article-title":"Genetic variations of NAT2 and CYP2E1 and isoniazid hepatotoxicity in a diverse population","volume":"10","author":"Yamada","year":"2009","journal-title":"Pharmacogenomics"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100136_bib377","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.5588\/ijtld.10.0648","article-title":"N-acetyltransferase 2 polymorphisms and risk of anti-tuberculosis drug-induced hepatotoxicity in Caucasians","volume":"15","author":"Leiro-Fernandez","year":"2011","journal-title":"Int J Tuberc Lung Dis"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100136_bib378","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/FPC.0000000000000232","article-title":"PharmGKB summary: isoniazid pathway, pharmacokinetics","volume":"26","author":"Klein","year":"2016","journal-title":"Pharmacogenet Genomics"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100136_bib379","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/jcph.1398","article-title":"The A\/A genotype of XPO1 rs4430924 is associated with higher risk of antituberculosis drug-induced hepatotoxicity in Chinese patients","volume":"59","author":"He","year":"2019","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100136_bib380","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/FPC.0000000000000370","article-title":"Association of FAM65B, AGBL4, and CUX2 genetic polymorphisms with susceptibility to antituberculosis drug-induced hepatotoxicity: validation study in a Chinese Han population","volume":"29","author":"Pan","year":"2019","journal-title":"Pharmacogenet Genomics"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100136_bib381","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/cpt.2100","article-title":"Genetic risk factors in drug-induced liver injury due to isoniazid-containing antituberculosis drug regimens","volume":"109","author":"Nicoletti","year":"2021","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100136_bib382","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.3390\/jcm13123563","article-title":"HLA-DPB1\u221705:01 and HLA-A\u221711:01 is associated with adverse drug reactions to isoniazid and Rifampin for treatment of latent tuberculosis infection in South Korea","volume":"13","author":"Kim","year":"2024","journal-title":"J Clin Med"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100136_bib383","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.tube.2011.12.004","article-title":"Genetic variants in antioxidant pathway: risk factors for hepatotoxicity in tuberculosis patients","volume":"92","author":"Nanashima","year":"2012","journal-title":"Tuberculosis (Edinb)"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100136_bib384","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3390\/pharmaceutics16030388","article-title":"Exploring variability in rifampicin plasma exposure and development of anti-tuberculosis drug-induced liver injury among patients with pulmonary tuberculosis from the pharmacogenetic perspective","volume":"16","author":"Kivrane","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.pharmr.2026.100136_bib385","series-title":"RIFATER\u00ae (rifampin isoniazid and pyrazinamide USP) tablets. [prescribing information]","year":"2023"},{"key":"10.1016\/j.pharmr.2026.100136_bib386","unstructured":"ClinPGx. Annotation of PMDA Label for isoniazid and NAT2. Accessed Aug 30, 2024. https:\/\/www.clinpgx.org\/labelAnnotation\/PA166161087"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100136_bib387","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1007\/s00228-012-1429-9","article-title":"NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy","volume":"69","author":"Azuma","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100136_bib388","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/FPC.0000000000000423","article-title":"A pilot study to investigate the utility of NAT2 genotype-guided isoniazid monotherapy regimens in NAT2 slow acetylators","volume":"31","author":"Yoo","year":"2021","journal-title":"Pharmacogenet Genomics"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100136_bib389","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1200\/JCO.2015.63.1325","article-title":"Upfront genotyping of DPYD\u22172A to individualize fluoropyrimidine therapy: a safety and cost analysis","volume":"34","author":"Deenen","year":"2016","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100136_bib390","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1146\/annurev-pharmtox-061724-080935","article-title":"Pharmacogenetic panel testing: a review of current practice and potential for clinical implementation","volume":"65","author":"Mosch","year":"2025","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"10374","key":"10.1016\/j.pharmr.2026.100136_bib391","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0140-6736(22)01841-4","article-title":"A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study","volume":"401","author":"Swen","year":"2023","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100136_bib392","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41397-023-00315-w","article-title":"The INGENIOUS trial: impact of pharmacogenetic testing on adverse events in a pragmatic clinical trial","volume":"23","author":"Eadon","year":"2023","journal-title":"Pharmacogenomics J"},{"issue":"16","key":"10.1016\/j.pharmr.2026.100136_bib394","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/ajhp\/zxae110","article-title":"Recommendations for pharmacogenetic testing in clinical practice guidelines in the US","volume":"81","author":"Hertz","year":"2024","journal-title":"Am J Health Syst Pharm"},{"issue":"D1","key":"10.1016\/j.pharmr.2026.100136_bib395","doi-asserted-by":"crossref","first-page":"D1498","DOI":"10.1093\/nar\/gkae1016","article-title":"PharmFreq: a comprehensive atlas of ethnogeographic allelic variation in clinically important pharmacogenes","volume":"53","author":"Tremmel","year":"2025","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100136_bib396","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/tan.12575","article-title":"Prevalence of HLA-B\u221757:01 allele in Argentinean HIV-1 infected patients","volume":"86","author":"Moragas","year":"2015","journal-title":"Tissue Antigens"},{"issue":"16","key":"10.1016\/j.pharmr.2026.100136_bib397","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1056\/NEJMra0911564","article-title":"Ancestry and disease in the age of genomic medicine","volume":"363","author":"Rotimi","year":"2010","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100136_bib398","doi-asserted-by":"crossref","first-page":"56","DOI":"10.4236\/ojgen.2014.41008","article-title":"Prevalence of human leukocyte antigen HLA-b\u22175701 in HIV-1 infected individuals in Brazil","volume":"4","author":"Ara\u00fajo Cd","year":"2014","journal-title":"Open J Genet"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100136_bib399","first-page":"510","article-title":"HLA-B\u22175701 frequency in Chilean HIV-infected patients and in general population","volume":"14","author":"Poggi","year":"2010","journal-title":"Braz J Infect Dis"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100136_bib400","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.humimm.2014.09.011","article-title":"The frequency of HLA-B(\u2217)57:01 and the risk of abacavir hypersensitivity reactions in the majority population of Costa Rica","volume":"75","author":"Arrieta-Bola\u00f1os","year":"2014","journal-title":"Hum Immunol"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100136_bib401","doi-asserted-by":"crossref","first-page":"809","DOI":"10.2217\/pgs.11.31","article-title":"Association of the genetic marker for abacavir hypersensitivity HLA-B\u2217 5701 with HCP5 rs2395029 in Mexican Mestizos","volume":"12","author":"Sanchez-Giron","year":"2011","journal-title":"Pharmacogenomics"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100136_bib402","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.3390\/ph14111077","article-title":"A comprehensive review of HLA and severe cutaneous adverse drug reactions: implication for clinical pharmacogenomics and precision medicine","volume":"14","author":"Kloypan","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100136_bib403","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation","volume":"138","author":"Zanger","year":"2013","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.pharmr.2026.100136_bib404","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.692234","article-title":"CYP2B6 functional variability in drug metabolism and exposure across populations-implication for drug safety, dosing, and individualized therapy","volume":"12","author":"Langmia","year":"2021","journal-title":"Front Genet"},{"key":"10.1016\/j.pharmr.2026.100136_bib405","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ebiom.2017.02.017","article-title":"African genetic diversity: implications for cytochrome P450-mediated drug metabolism and drug development","volume":"17","author":"Rajman","year":"2017","journal-title":"EBiomedicine"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100136_bib406","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s00228-018-2441-5","article-title":"Mortality among patients due to adverse drug reactions that lead to hospitalization: a meta-analysis","volume":"74","author":"Patel","year":"2018","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.pharmr.2026.100136_bib407","doi-asserted-by":"crossref","first-page":"350","DOI":"10.3389\/fphar.2018.00350","article-title":"Adverse drug reactions in hospitalized patients: results of the FORWARD (facilitation of reporting in hospital Ward) study","volume":"9","author":"Giardina","year":"2018","journal-title":"Front Pharmacol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100136_bib408","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/FPC.0000000000000024","article-title":"PharmGKB summary: very important pharmacogene information for UGT1A1","volume":"24","author":"Barbarino","year":"2014","journal-title":"Pharmacogenet Genomics"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100136_bib409","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/humu.24336","article-title":"Qatar genome: insights on genomics from the Middle East","volume":"43","author":"Mbarek","year":"2022","journal-title":"Hum Mutat"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100136_bib411","doi-asserted-by":"crossref","first-page":"5929","DOI":"10.1038\/s41467-021-25287-y","article-title":"Thousands of Qatari genomes inform human migration history and improve imputation of Arab haplotypes","volume":"12","author":"Razali","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100136_bib412","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ajhg.2010.05.018","article-title":"Population genetic structure of the people of Qatar","volume":"87","author":"Hunter-Zinck","year":"2010","journal-title":"Am J Hum Genet"},{"issue":"Database issue","key":"10.1016\/j.pharmr.2026.100136_bib413","doi-asserted-by":"crossref","first-page":"D602","DOI":"10.1093\/nar\/gkj015","article-title":"CTGA: the database for genetic disorders in Arab populations","volume":"34","author":"Tadmouri","year":"2006","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100136_bib414","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1109\/MPUL.2015.2476541","article-title":"The Saudi Human Genome Program: an oasis in the desert of Arab medicine is providing clues to genetic disease","volume":"6","year":"2015","journal-title":"IEEE Pulse"},{"issue":"Suppl 1","key":"10.1016\/j.pharmr.2026.100136_bib415","article-title":"Individualized medicine enabled by genomics in Saudi Arabia","volume":"8","author":"Abu-Elmagd","year":"2015","journal-title":"BMC Med Genomics"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100136_bib416","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41525-022-00281-5","article-title":"A population study of clinically actionable genetic variation affecting drug response from the Middle East","volume":"7","author":"Jithesh","year":"2022","journal-title":"NPJ Genom Med"},{"key":"10.1016\/j.pharmr.2026.100136_bib417","doi-asserted-by":"crossref","DOI":"10.1016\/j.humgen.2024.201324","article-title":"A prospective epidemiological investigation of human leukocyte antigen-B\u221757:01 in HIV-1-infected Moroccan subjects","volume":"42","author":"Belbacha","year":"2024","journal-title":"Hum Gene"},{"key":"10.1016\/j.pharmr.2026.100136_bib418","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1423636","article-title":"HLA-B allele frequencies and implications for pharmacogenetics in the Kuwaiti population","volume":"15","author":"Dashti","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.pharmr.2026.100136_bib419","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/5754776","article-title":"Frequency of CYP2B6 alleles in major Iranian ethnicities, affecting response to efavirenz","volume":"2022","author":"Mardi","year":"2022","journal-title":"Genet Res (Camb)"},{"key":"10.1016\/j.pharmr.2026.100136_bib420","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/8703812","article-title":"Frequencies of CYP2B6\u22174,\u22175, and \u22176 alleles within an Iranian population (Mazandaran)","volume":"2021","author":"Hashemi-Soteh","year":"2021","journal-title":"Genet Res (Camb)"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100136_bib421","first-page":"685","article-title":"Genetic variability of CYP2B6 polymorphisms in southeast Iranian population: implications for malaria and HIV\/AIDS treatment","volume":"17","author":"Zakeri","year":"2014","journal-title":"Arch Iran Med"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100136_bib422","doi-asserted-by":"crossref","DOI":"10.1002\/cpz1.226","article-title":"PharmGKB, an integrated resource of pharmacogenomic knowledge","volume":"1","author":"Gong","year":"2021","journal-title":"Curr Protoc"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100136_bib423","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.cell.2019.02.048","article-title":"The missing diversity in human genetic studies","volume":"177","author":"Sirugo","year":"2019","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100136_bib424","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/bcp.14983","article-title":"Health equality, race and pharmacogenomics","volume":"88","author":"Magavern","year":"2022","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100136_bib425","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/cpt.1491","article-title":"The advantages and challenges of diversity in pharmacogenomics: can minority populations bring us closer to implementation?","volume":"106","author":"Zhang","year":"2019","journal-title":"Clin Pharmacol Ther"},{"issue":"9742","key":"10.1016\/j.pharmr.2026.100136_bib426","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0140-6736(10)60396-0","article-title":"The rise and fall of the antimalarial Lapdap: a lesson in pharmacogenetics","volume":"376","author":"Luzzatto","year":"2010","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100136_bib427","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3390\/jpm11030179","article-title":"Pharmacogenomic biomarkers in US FDA-approved drug labels (2000\u20132020)","volume":"11","author":"Kim","year":"2021","journal-title":"J Pers Med"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100136_bib428","doi-asserted-by":"crossref","first-page":"51","DOI":"10.5688\/ajpe75351","article-title":"Assessment of the pharmacogenomics educational needs of pharmacists","volume":"75","author":"McCullough","year":"2011","journal-title":"Am J Pharm Educ"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100136_bib429","doi-asserted-by":"crossref","first-page":"800","DOI":"10.3390\/jpm11080800","article-title":"Pharmacogenomics: from basic research to clinical implementation","volume":"11","author":"Scheinfeldt","year":"2021","journal-title":"J Pers Med"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100136_bib430","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/tpj.2014.86","article-title":"Pharmacogenomic information in drug labels: European Medicines Agency perspective","volume":"15","author":"Ehmann","year":"2015","journal-title":"Pharmacogenomics J"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100136_bib431","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0146262","article-title":"Economic evaluations of pharmacogenetic and pharmacogenomic screening tests: a systematic review. Second update of the literature","volume":"11","author":"Berm","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100136_bib432","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/cpt.1944","article-title":"Global frequencies of clinically important HLA alleles and their implications for the cost-effectiveness of preemptive pharmacogenetic testing","volume":"109","author":"Zhou","year":"2021","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100136_bib435","article-title":"Bridging genomics' greatest challenge: the diversity gap","volume":"5","author":"Corpas","year":"2025","journal-title":"Cell Genom"},{"key":"10.1016\/j.pharmr.2026.100136_bib436","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.pharmthera.2017.02.036","article-title":"Personalized medicine: genetic risk prediction of drug response","volume":"175","author":"Zhang","year":"2017","journal-title":"Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100136_bib437","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.5345","article-title":"Projected prevalence of actionable pharmacogenetic variants and Level A drugs prescribed among US Veterans Health Administration pharmacy users","volume":"2","author":"Chanfreau-Coffinier","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100136_bib438","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/s41431-018-0300-6","article-title":"Genetic variation in the Estonian population: pharmacogenomics study of adverse drug effects using electronic health records","volume":"27","author":"Tasa","year":"2019","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.pharmr.2026.100136_bib439","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1146\/annurev-pharmtox-030823-111731","article-title":"Addressing ancestry and sex bias in pharmacogenomics","volume":"64","author":"Corpas","year":"2024","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.pharmr.2026.100136_bib440","series-title":"Exploring Barriers to the Adoption of Pharmacogenomic Technology in the Clinical Setting by Clinical Healthcare Providers. Dissertations and Theses (ETDs)","author":"Sudia","year":"2016"},{"key":"10.1016\/j.pharmr.2026.100136_bib441","series-title":"Global Perspectives on Precision Medicine: Ethical, Social and Public Health Implications","first-page":"125","article-title":"Social and ethical implications of integrating precision medicine into healthcare","author":"Sarwar","year":"2023"},{"issue":"D1","key":"10.1016\/j.pharmr.2026.100136_bib443","doi-asserted-by":"crossref","first-page":"D1265","DOI":"10.1093\/nar\/gkad976","article-title":"DrugBank 6.0: the DrugBank knowledgebase for 2024","volume":"52","author":"Knox","year":"2024","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100136_bib444","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/infdis\/jis499","article-title":"Distinct phases of blood gene expression pattern through tuberculosis treatment reflect modulation of the humoral immune response","volume":"207","author":"Cliff","year":"2013","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100136_bib445","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1093\/infdis\/jiv447","article-title":"Excessive cytolytic responses predict tuberculosis relapse after apparently successful treatment","volume":"213","author":"Cliff","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.pharmr.2026.100136_bib446","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.tube.2017.08.004","article-title":"hosts. Host blood RNA signatures predict the outcome of tuberculosis treatment","volume":"107","author":"Thompson","year":"2017","journal-title":"Tuberculosis (Edinb)"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100136_bib447","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0045839","article-title":"Genome-wide expression profiling identifies type 1 interferon response pathways in active tuberculosis","volume":"7","author":"Ottenhoff","year":"2012","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100136_bib448","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S2213-2600(16)00048-5","article-title":"Genome-wide expression for diagnosis of pulmonary tuberculosis: a multicohort analysis","volume":"4","author":"Sweeney","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100136_bib449","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0173304","article-title":"Serum amyloid A, protein Z, and C4b-binding protein \u03b2 chain as new potential biomarkers for pulmonary tuberculosis","volume":"12","author":"Jiang","year":"2017","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100136_bib450","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0231834","article-title":"Proteomic analysis of infected primary human leucocytes revealed PSTK as potential treatment-monitoring marker for active and latent tuberculosis","volume":"15","author":"Kaewseekhao","year":"2020","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100136_bib451","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.tube.2014.01.006","article-title":"Aptamer-based proteomic signature of intensive phase treatment response in pulmonary tuberculosis","volume":"94","author":"Nahid","year":"2014","journal-title":"Tuberculosis (Edinb)"},{"key":"10.1016\/j.pharmr.2026.100136_bib452","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jprot.2016.06.016","article-title":"Serum inflammatory profiles in pulmonary tuberculosis and their association with treatment response","volume":"149","author":"Choi","year":"2016","journal-title":"J Proteomics"},{"key":"10.1016\/j.pharmr.2026.100136_bib453","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.108980","article-title":"l-histidine, arachidonic acid, biliverdin, and l-cysteine-glutathione disulfide as potential biomarkers for cured pulmonary tuberculosis","volume":"116","author":"Yi","year":"2019","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100136_bib454","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-75513-8","article-title":"Integration of metabolomics and transcriptomics reveals novel biomarkers in the blood for tuberculosis diagnosis in children","volume":"10","author":"Dutta","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.pharmr.2026.100136_bib455","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1016\/j.tube.2016.09.022","article-title":"Predictive value of serum bradykinin and desArg9-bradykinin levels for chemotherapeutic responses in active tuberculosis patients: a retrospective case series","volume":"101S","author":"Qian","year":"2016","journal-title":"Tuberculosis (Edinb)"},{"key":"10.1016\/j.pharmr.2026.100136_bib456","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12014-016-9127-8","article-title":"Precision medicine: from pharmacogenomics to pharmacoproteomics","volume":"13","author":"Chambliss","year":"2016","journal-title":"Clin Proteomics"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100136_bib457","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.mjafi.2021.06.021","article-title":"Precision medicine: concept and tools","volume":"77","author":"Naithani","year":"2021","journal-title":"Med J Armed Forces India"},{"key":"10.1016\/j.pharmr.2026.100136_bib458","series-title":"Texts in Applied Mathematics","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4939-9828-9_4","article-title":"Mathematical models in epidemiology","author":"Brauer","year":"2019"},{"key":"10.1016\/j.pharmr.2026.100136_bib459","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.pnpbp.2017.10.005","article-title":"Pleiotropic genes in psychiatry: calcium channels and the stress-related FKBP5 gene in antidepressant resistance","volume":"81","author":"Fabbri","year":"2018","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100136_bib460","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0205872","article-title":"Ensemble of machine learning algorithms using the stacked generalization approach to estimate the warfarin dose","volume":"13","author":"Ma","year":"2018","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100136_bib461","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0135784","article-title":"Comparison of nine statistical model based warfarin pharmacogenetic dosing algorithms using the racially diverse international warfarin pharmacogenetic consortium cohort database","volume":"10","author":"Liu","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmr.2026.100136_bib462","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/560108","article-title":"Revisiting warfarin dosing using machine learning techniques","volume":"2015","author":"Sharabiani","year":"2015","journal-title":"Comput Math Methods Med"},{"key":"10.1016\/j.pharmr.2026.100136_bib463","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2020.103634","article-title":"Evaluating warfarin dosing models on multiple datasets with a novel software framework and evolutionary optimisation","volume":"113","author":"Truda","year":"2021","journal-title":"J Biomed Inform"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100136_bib464","doi-asserted-by":"crossref","first-page":"583","DOI":"10.2217\/pgs.15.26","article-title":"Comparison of the predictive abilities of pharmacogenetics-based warfarin dosing algorithms using seven mathematical models in Chinese patients","volume":"16","author":"Li","year":"2015","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.pharmr.2026.100136_bib465","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jpsychires.2017.12.009","article-title":"GWAS-based machine learning approach to predict duloxetine response in major depressive disorder","volume":"99","author":"Maciukiewicz","year":"2018","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.pharmr.2026.100136_bib466","doi-asserted-by":"crossref","DOI":"10.1016\/j.compeleceng.2024.109370","article-title":"A review of Explainable Artificial Intelligence in healthcare","volume":"118","author":"Sadeghi","year":"2024","journal-title":"Comput Electr Eng"}],"container-title":["Pharmacological Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699726000244?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699726000244?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T10:22:52Z","timestamp":1785147772000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031699726000244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":446,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0031699726000244"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmr.2026.100136","relation":{},"ISSN":["0031-6997"],"issn-type":[{"value":"0031-6997","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacogenomics of antibacterial and antiviral therapies: Clinical actionability, evidence gaps, and future directions","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmr.2026.100136","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"100136"}}